2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruan, X. Z. Articles by Varghese, Z. Search for Related Content PubMed PubMed Citation Articles by Ruan, X. Z. Articles by Varghese, Z.

PPAR Agonists Protect Mesangial Cells from Interleukin 1-Induced Intracellular Lipid Accumulation by Activating the ABCA1 Cholesterol Efflux Pathway

Centre for Nephrology, Royal Free and University College Medical School, London, United Kingdom.

Correspondence to Dr. Zac Varghese, Centre for Nephrology, Royal Free and University College Medical School, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK. Phone: 44-20-7830-2190; Fax: 44-20-7830-2125;

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
ABSTRACT. Previous studies have demonstrated that inflammatory cytokines such as interleukin-1 (IL-1) promote lipid accumulation in human mesangial cells (HMC) by dysregulating the expression of lipoprotein receptors. Intracellular lipid accumulation is governed by both influx and efflux; therefore, the effect of IL-1 on the efflux of lipid from HMC was investigated. IL-1 was shown to inhibit ³H-cholesterol efflux from HMC and increase total intracellular cholesterol concentration, probably as a result of reduced expression of the adenosine triphosphate (ATP) binding cassette A1 (ABCA1), a transporter protein involved in apolipoprotein-A1 (apo-A1)–mediated lipid efflux. To ascertain the molecular mechanisms involved, expression of peroxisome proliferator-activated receptors (PPAR) and liver X receptor (LXR) were examined. IL-1 (5 ng/ml) reduced PPAR, PPAR, and LXR mRNA expression. Activation of PPAR with the agonist prostaglandin J2 (10 µM) and of PPAR with either bezafibrate (100 µM) or Wy14643 (100 µM) both increased LXR and ABCA1 gene expression also and enhanced apoA1-mediated cholesterol efflux from lipid-loaded cells, even in the presence of IL-1. A natural ligand of LXR, 25-hydroxycholesterol (25-OHC), had similar effects; when used together with PPAR agonists, an additive effect was observed, indicating co-operation between PPAR and LXR in regulating ABCA1 gene expression. This was supported by the observation that overexpression of either PPAR or PPAR by transfection enhanced LXR and ABCA1 gene induction by PPAR agonists. Taken together with previous data, it appears that, in addition to increasing lipid uptake, inflammatory cytokines promote intracellular lipid accumulation by inhibiting cholesterol efflux through the PPAR-LXR-ABCA1 pathway. These results suggest potential mechanisms whereby inflammation may exacerbate lipid-mediated cellular injury in the glomerulus and in other tissues and indicate that PPAR agonists may have a protective effect. E-mail: zvarghese@rfc.ucl.ac.uk

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Clinical studies indicate that correction of dyslipidemia associated with kidney disease may slow progression of chronic renal failure (1). Inflammation, lipid accumulation, and foam cell formation are recognized features of glomerular and tubulointerstitial injury, and it is plausible that renal injury and atherosclerosis share common pathogenic mechanisms (2,3). In most cells, intracellular cholesterol accumulation is prevented by tight regulation of influx and efflux pathways (4). It is generally accepted that intracellular cholesterol accumulation only occurs in cells, such as macrophages, that are able to take up modified lipoproteins via a scavenger-type receptor (5). We have previously demonstrated that cytokines induce scavenger receptor expression by mesangial cells and promote foam cell formation (6). However, we also observed that under inflammatory conditions, intracellular lipid accumulation occurred even when scavenger receptors were blocked with polyisonosinic acid, suggesting that additional pathways were involved. Further studies indicated that inflammatory cytokines caused dysregulation of LDL receptor expression, which is usually tightly controlled by intracellular cholesterol concentration (7), thereby allowing unregulated uptake of cholesterol.

Intracellular lipid content is governed by both influx and efflux; we therefore set out to examine the impact of inflammatory cytokines on cholesterol efflux, a process mediated by the protein adenosine triphosphate (ATP) binding cassette A1 (ABCA1). ABCA1, a member of the ATP binding cassette (ABC) transporter super family, is a cholesterol transporter containing 12 putative transmembrane domains and two ABC (8,9). ABCA1 deficiency causes both Tangier disease and familial HDL deficiency, characterized by accumulation of cholesterol esters in various tissues such as tonsils, liver, spleen, and intestinal mucosa. Individuals with these disorders have very low levels of plasma HDL cholesterol (10,11). ABCA1 is dramatically induced in lipid-loaded macrophages and facilitates the efflux of cellular cholesterol to extracellular apoA1 or HDL. ABCA1 activation seems to be the first step of the reverse cholesterol transport pathway and is therefore important in the control of plasma level of HDL, which is an important factor in the development of atherosclerosis (12,13).

It has been recently demonstrated that ABCA1 gene expression in macrophages can be induced by PPAR, PPAR, and LXR agonists (14–16). PPAR are ligand-activated nuclear receptors, which upon heterodimerization with the retinoid X receptors (RXR) induce a number of genes controlling lipid and glucose metabolism, cellular differentiation, and inflammation (17–19). The LXR were originally cloned as orphan receptors based on their homology to RXR. LXR, which is known to regulate the metabolic conversion of cholesterol to bile acids, has also been shown to regulate the expression of ABCA1 in macrophages and fibroblasts (15,16). A PPAR response element has been identified in the LXR gene promoter; it therefore seems likely that PPAR regulate ABCA1 gene expression through the LXR pathway.

The ability of ABCA1 to facilitate cholesterol efflux suggests that it may be a useful target for intervention in human diseases involving lipid accumulation. The present study examines the effects of the inflammatory cytokine IL-1 on cholesterol efflux in human mesangial cells (HMC), investigates the underlying molecular mechanisms and explores the potential protective influence of PPAR and LXR agonists on lipid-mediated injury.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cell Culture
An established stable line of HMC that had been immortalized by transfection with T-SV40 and H-ras oncogenes was used in all experiments (kindly donated by Dr. J. D. Sraer, Hôpital Tenon, Paris). These cells have been fully characterized and retain most of the morphologic and physiologic features of nontransfected mesangial cells (20,21). These cells were cultured in growth medium comprising RPMI supplemented with 5% fetal calf serum (FCS), 2 mmol/L glutamine, 100 unit/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin, 5 µg/ml insulin, 5 µg/ml human transferrin, and 5 ng/ml sodium selenite. Experiments were carried out in serum-free RPMI medium containing 0.2% bovine serum albumin (BSA; Sigma, Poole, Dorset, UK). All reagents for cell culture were obtained from Life Technologies BRL (Paisley, UK). Recombinant interleukin-1 (IL-1, 1.0 to 3.3 x 10⁸ U/mg) was obtained from R&D Systems (Europe Ltd, Abingdon, UK).

Transient Expression of PPAR
HMC were cultured and transfected with supercoiled PPAR or PPAR expressive vectors (pSG5hPPAR and pSG5hPPAR, kindly provided by Professor B. Staels, Lille, France) by electroporation at 340 V and 125 uF with a Gene Pulser (Bio-Rad, Hemel Hempstead, Herefordshire, UK). After electroporation, the cells were placed in six-well plates with growth medium. Approximately 24 h after replating, cells were washed with PBS and the medium was replaced by fresh serum-free RPMI medium in the presence or absence of bezafibrate (100 µM) or PPAR agonist PGJ2 (10 µM) for 24 h. The cells were then collected and RNA was analyzed.

Reverse Transcriptase–PCR
Total RNA (500 ng) was used as a template for RT-PCR using an RNA PCR kit from ABI (Applied Biosystems, Warrington, Cheshire, UK). The RT reaction was set up in a 20 µl mixture containing 50 mmol/L KCl, 10 mmol/L Tris/HCl, 5 mmol/L MgCl₂, 1 mmol/L of each dNTP, 2.5 µmol/L random hexamers, 20 U RNAsin, and 50 U of M-MLV reverse transcriptase. Incubations were performed in a DNA Thermal Cycler (Perkin-Elmer 9700) for 10 min at room temperature, followed by 30 min at 42°C and 5 min at 99°C. After cDNA synthesis by RT, the incubation mixture was split into two 10-µl aliquots for separate amplification of ABCA1, PPAR, PPAR, LXR, and GAPDH cDNA using specific primers. The final concentrations of the PCR reaction mixture were 50 mmol/L KCl, 10 mmol/L Tris/HCl, 2 mmol/L MgCl_2, 200 µmol/L dNTP, 0.125 µmol/L of primers, 1.25 U Taq DNA polymerase. The following primers were used for PCR. ABCA1 upper primer (nucleotide positions 4503–4523) 5'-TTAAACGCCCTCACCAAAGAC-3', and lower primer (4873–4896) 5'-AAAAGCCGCCATACCTAAACTCAT-3', PPAR upper primer (733–757) 5'-GACGAATGCCAAGATCTGAGAAAGC-3' and lower primer (1660–1683) 5'-CGTCTCCTTTGTAGTGCTGTCAGC-3', PPAR upper primer (493–522) 5'-GGCAATTGAATGTCGTGTCTGTGGAGATAA-3' and lower primer (1402–1432) 5'-AGCTCCAGGGCTTGTAGCAGGTTGTCTTGA-3', LXR upper primer (379–399) 5'-GCGAGGGCTGCAAGGGATTCT-3' and lower primer (735–754) 5'-ATGGGCCAAGGCGTGACTCG-3', GAPDH upper primer (nucleotide positions 73–92) 5'-TCATAGACAAGATGGTGAAG-3', and lower primer (303–327) 5'-TGACGGGATCTCGCTCCTGGAAGAT-3' (22). Twenty microliters of each PCR reaction were subjected to electrophoresis in a 2% agarose gel.

Southern Blot Analyses and Quantitative Evaluation
Nucleic acids were transferred to a nylon membrane (Boehringer Mannheim, Lewes, East Sussex, UK) using the Southern analysis method. The nylon membranes were probed with [-³²P]ATP labeled oligonucleotides (3000 Ci/mmol; Amersham, Little Chalfont, Buckinghamshire, UK). The following probes were used: ABCA1 probe (nucleotide position 4552–4575) 5'-AGGGCGTGTCTGGGATTGGGTTTC-3', PPAR probe (1456–1479) 5'-AGAGAAAGATATCGTCCGGGTGGT-3', PPAR probe (878 to 898): 5'-TGTCTTTCCTGTCAAGATCGC-3'), LXR probe (410–433) 5'-ATGTAGTGCGCTCCCTTGATGACG-3', and GAPDH probe (170–191) 5'-AATGAAGGGGTCGTTGATGGCA-3' (22). The DNA probes were labeled using a 5'-end labeling system (Promega, Southampton, Hampshire, UK). Membranes were irradiated by UV stratalinker for 3 min, prehybridized in 50% formamide, 5 x Denhardt solution, 5 x SSPE, 100 µg/ml hs DNA, and 50 mmol/L sodium phosphate (pH 6.8) at 42°C for 4 h, and hybridized overnight at 42°C with at least 1 x 10⁶ cpm/ml of the labeled probe in the same solution used for prehybridization but without Denhardt reagents. The membranes were washed twice for 15 min at room temperature with 5 x SSC, and then washed for 10 min at 42°C with 5 x SSC. The blots were exposed to x-ray films (Eastman Kodak, Rochester, NY) for 4 h.

Cholesterol Loading and Cholesterol Efflux Assay
Oxidized LDL (Ox-LDL) was prepared from human LDL as described previously (23). HMC were incubated with medium A, which contains RPMI 1640, 1% CPSR (low lipid serum replacement; Sigma, Poole, Dorset, UK), 1 µl of [³H] cholesterol (1 µCi/µl; Amersham, Little Chalfont, Buck, UK), and 50 µg/ml of Ox-LDL. After 72 h, the fresh serum-free medium containing PPAR agonists Bezafibrate (100 µM) or Wy14643 (100 µM), or PPAR agonist PGJ2 (10 µM) were added in the presence or absence of the inflammatory cytokine IL-1 (5 ng/ml) for a further 24 h. The oxysterol 25-OHC (1 µg/ml) was also used as an agonist of LXR. After this incubation period, cells were washed twice in PBS, and apoA1-mediated cholesterol efflux studies were immediately performed by adding fresh serum-free RPMI 1640 medium with or without 50 µg/ml of ApoA1 for 24 h. At the end of this incubation, the supernatant was collected and centrifuged at 13,000 rpm for 10 min. Cellular lipids was extracted using isopropanol. The radioactivity in both the supernatant and cellular lipid was measured by scintillation counting. ApoA1-induced [³H]-cholesterol efflux was calculated as by subtracting the radioactivity in supernatants without apoA from the counts in supernatants containing apo A. The data were normalized by determining total [³H]-cholesterol radioactivity (including radioactivity in supernatant and cell) and were expressed as a percentage of control.

Total Cholesterol Measurement
HMC were cultured in six-well plates and loaded with cholesterol as described above. After 72 h, cells were cultured in serum-free medium without (control) or with 5 ng/ml of IL-1 for 24 h. Cells were then washed twice in PBS and incubated with 50 µg/ml of ApoA1 for a further 24 h. At the end of this second incubation period, intracellular lipids were extracted in isopropanol and dried under vacuum, and the total cholesterol content was measured by enzymatic assay (Dade Behring, Milton Keynes, UK). Cellular proteins were collected by digestion in NaOH and measured by the Bradford assay (BioRad, Hertfordshire, UK). The results were normalized for total cellular protein.

Statistical Analyses
In all experiments, data were evaluated for significance by one-way ANOVA using Minitab software. Data were considered significant at P 0.05.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
We examined the effects of the inflammatory cytokine IL-1 on cholesterol efflux. At a concentration of 5 ng/ml, IL-1 reduced Apo-A1-mediated cholesterol efflux from lipid-loaded HMC (Figure 1A) and increased intracellular total cholesterol content (Figure 1B). To investigate the potential mechanisms by which this occurred, the effect of IL-1 on expression of the ABCA1 gene was studied. IL-1 reduced ABCA1 gene expression in a time-dependent manner in both non-lipid–loaded (Figure 2A) and lipid-loaded HMC (Figure 2B). Interestingly, IL-1 also inhibited both PPAR and LXR mRNA expression with a similar temporal response pattern (Figure 3, A through C). These results suggest that both PPAR and LXR may regulate the ABCA1 pathway and thereby mediate the reduction in cholesterol efflux induced by IL-1.

View larger version (13K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 1. IL-1 reduced cholesterol efflux in human mesangial cells (HMC). Lipid-loaded HMC were treated with serum-free medium without (control) or with IL-1 (5 ng/ml) for 24 h. The cells were subsequently incubated in serum-free RPMI 1640 medium with or without 50 µg/ml of ApoA for 24 h. ApoA1-mediated [3H] cholesterol efflux (A) and total intracellular cholesterol (B) were measured as described in the Materials and Methods section. Results are expressed as percentage of the untreated control. * P < 0.001 versus control.

View larger version (21K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 2. The effects of IL-1 on ABCA1 gene expression. HMC were incubated in serum-free medium for 24 h, then fresh medium containing IL-1 (5 ng/ml) was added and cells were cultured for 0 (control), 6, 24, and 48 h (A). In addition, lipid-loaded HMC were treated with IL-1 (5 ng/ml) for 24 h (B). The expression of ABCA1 mRNA, was examined using RT-PCR followed by Southern blotting as described in Materials and Methods.

View larger version (27K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 3. The effects of the inflammatory cytokine IL-1 on peroxisome proliferator-activated receptors (PPAR) and liver X receptor (LXR) gene expression. HMC were incubated in serum-free medium for 24 h, then the medium was changed to a fresh medium containing IL-1 (5 ng/ml) and cells were cultured for 0 (control), 6, 24, and 48 h (A, B, C). Both PPAR and LXR mRNA were examined using RT-PCR followed by Southern blotting as described in Materials and Methods.

View larger version (21K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 4. PPAR agonists increased apoA1-mediated cholesterol efflux from lipid-loaded HMC. Lipid-loaded HMC were treated with vehicle (control), bezafibrate (100 µM), Wy14643 (100 µM), or PGJ2 (10 µM) in the presence or absence of IL-1 (5 ng/ml) for 24 h. The cells were subsequently incubated in serum-free RPMI 1640 medium with or without 50 µg/ml of ApoA1 for 24 h. ApoA1-mediated [3H] cholesterol efflux was measure as described in Materials and Methods. Results are expressed as a percentage of the untreated control. *P < 0.05 versus control, **P < 0.001 versus control, ***P < 0.05 versus IL-1 alone.

View larger version (22K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 5. The effect of 25-OHC on ABCA1-mediated cholesterol efflux. Lipid-loaded HMC were treated with vehicle (control) or 25-OHC (1 µg/ml) in the presence or absence of bezafibrate (100 µM) or PGJ2 (10 µM) for 24 h. The cells were subsequently incubated in serum-free RPMI 1640 medium with or without 50 µg/ml of ApoA1 for 24 h. ApoA1-mediated [3H] cholesterol efflux was measured. *P < 0.001 versus control.

View larger version (20K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 6. The effect of PPAR agonists on PPAR gene expression. HMC were incubated in serum-free medium with vehicle (control) or serum-free medium containing various concentrations of bezafibrate (10, 50, 100, 200 µM) or PGJ2 (1, 5, 10, 20 µM) for 24 h. The expression of both PPAR and PPAR mRNA was examined respectively.

View larger version (32K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 7. The effect of PPAR agonists on LXR gene expression. HMC were incubated with vehicle (control), various concentration of bezafibrate (5, 10, 50, 100, 200 µM) or PGJ2 (1, 2.5, 5, 10, 20 µM) for 24 h (A and B), or the cells were incubated with 100 µM of bezafibrate or 10 µM of PGJ2 for different times (C). The expression of LXR mRNA was examined.

View larger version (21K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 8. The lipid-loaded cells were treated with vehicle (control), bezafibrate (100 µM), or PGJ2 (10 µM) for 24 h (A). In addition, lipid-loaded HMC were also treated with IL-1 (5 ng/ml) in the absence or presence of bezafibrate (100 µM) or PGJ2 (10 µM) for 24 h (B). HMC were also transfected by PPAR or PPAR expressive vectors. The transfected cells were loaded with lipid and treated with vehicle (control) or bezafibrate (100 µM) or PGJ2 (10 µM) for 24 h (A). The expression of LXR mRNA was examined.

View larger version (19K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 9. Both PPAR and PPAR agonists induced ABCA1 mRNA expression in HMC. HMC were incubated in serum-free medium with vehicle (control) or in serum-free medium containing various concentrations of bezafibrate (10, 100, 200 µM) or PGJ2 (1, 10, 20 µM) for 24 h (A and B). The expression of ABCA1 mRNA was examined.

View larger version (32K): [in this window] [in a new window] [as a PowerPoint slide]   Figure 10. The lipid-loaded cells were treated with vehicle (control), bezafibrate (100 µM), or PGJ2 (10 µM) for 24 h (A). In addition, the lipid-loaded cells also were treated with vehicle (control) or IL-1 (5 ng/ml) in the absence (control) or presence of 100 µM of bezafibrate or 10 µM of PGJ2 for 24 h. The expression of ABCA1 mRNA was examined (B). HMC were also transfected by PPAR or PPAR expressive vectors. The transfected cells were loaded with lipid. The cells then were treated with bezafibrate (100 µM) or PGJ2 (10 µM) for 24 h (A). The expression of ABCA1 mRNA was examined. Lipid-loaded HMC were also incubated with vehicle (control) or 25-OHC (1 µg/ml) in the absence or presence of 100 µM of bezafibrate or 10 µM of PGJ2 for 24 h (C), the ABCA1 gene expression was examined as described in Materials and Methods.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Furthermore, we investigated the molecular mechanisms that may contribute to cytokine-induced dysregulation of cholesterol efflux. Several studies have confirmed that ABCA1 expression is induced by lipid-loading of macrophages, whereas studies using antisense oligonucleotides have supported the role of this protein in facilitating the efflux of cholesterol to extracellular apo A1 or to HDL. Moreover, fibroblasts derived from patients with Tangier disease (24) or from ABCA1 null mice (25) exhibit a 60% reduction in the rate of efflux of cholesterol and phospholipids to extracellular acceptors. Taken together, these observations indicate that ABCA1 activation is the first step in the reverse cholesterol transport pathway and regulates plasma levels of HDL, a lipoprotein that is recognized to protect against atherosclerosis (12,13). Defective efflux of cellular cholesterol is also thought to account for the low levels of plasma HDL observed in ABCA1 null mice and in familial HDL deficiency, an inherited condition in which an ABCA1 gene mutation has been described (11,13). Our results demonstrating that IL-1 inhibits ABCA1 mRNA expression provide a plausible mechanism by which this inflammatory cytokine might impair cellular cholesterol efflux. Inhibition of the ABCA1 pathway by inflammatory cytokines might also explain the clinical observation that patients with an activated inflammatory response have low circulating levels of apo A1 (26).

We next describe how IL-1 inhibits ABCA1 gene expression. PPAR control the expression of a number of genes involved with lipid metabolism, including ABCA1 (14); we therefore examined whether these ligand-activated nuclear receptors might be involved in cytokine-induced downregulation of the cholesterol efflux protein. There are three types of PPAR, termed , (), and , all of which belong to the nuclear receptor super family. PPAR is highly expressed in liver, heart, muscle, kidney,and cells of the arterial wall (such as endothelial cells, smooth muscle cell, and monocyte-derived macrophages) and can be activated by fatty acids, eicosanoids, and lipid-lowering drugs of the fibrate class; PPAR has a much more restricted expression,and its ligands are prostaglandin J2, oxidized fatty acids, and thiazolidinedione (glitazone)-type antidiabetic agents (27,28). After binding to respective ligands in the nucleus, PPAR change conformation and interact with the peroxisome proliferator response element (PPRE), thereby promoting activation of target genes (18). We observed that IL-1 caused suppression of both PPAR and PPAR mRNA expression over a time scale that would be consistent with their role in regulating ABCA1 gene transcription. This observation suggests that PPAR may mediate the inhibition of ABCA1 gene induced by IL-1.

Importantly, we demonstrated that agonists of PPAR and PPAR increased ABCA1 gene expression and cholesterol efflux, even in the presence of IL-1, suggesting that PPAR activation may have a protective role in preventing lipid accumulation by overriding the reduction in cholesterol efflux induced by inflammatory cytokines. There is no recognized PPAR regulatory element in the ABCA1 gene promoter region; we therefore examined the role of other potential mediators. One obvious candidate was LXR, which has been identified as an ABCA1 gene regulator (16) and has a PPAR response element (PPRE) in its gene promoter region (29). The involvement of the PPAR-LXR-ABCA1 pathway in mediating cholesterol efflux has previously been reported (30). We therefore, investigated the role of the interaction of PPAR and LXR in the regulation of ABCA1 gene expression. Our results show that both PPAR and PPAR activation induced LXR genes expression, even in the presence of the inflammatory cytokine IL-1. 25-OHC, an LXR agonist, also increased ABCA1 gene expression and cholesterol efflux in HMC. The induction of LXR and ABCA1 genes was further increased when both PPAR and PPAR gene were overexpressed in HMC. This is probably due to direct induction of LXR gene transcription as a result of PPAR interacting with PPRE in the LXR promoter (29). Finally, we examined the effect of the combination of PPAR and LXR on ABCA1 gene expression. The combination of both PPAR and LXR agonists had an additive effect in increased ABCA1 gene expression and cholesterol efflux. This would suggest that the effects of PPAR agonists on ABCA1 gene expression might be mediated by their stimulatory action on LXR expression and activity. Thus PPAR and LXR appear to act jointly to control ABCA1-mediated cholesterol efflux in HMC. To further clarify the relationship between PPAR and LXR or PPAR and ABCA1 genes, PPAR or LXR null cells will be required.

Taken together with our previous studies of mesangial cell lipid uptake, our results suggest that there may be several mechanisms that cause intracellular lipid accumulation in the presence of an inflammatory response. To avoid intracellular accumulation of lipid, there must be a functional balance between influx via lipoprotein receptors and efflux via the ABCA1 or other pathways. Inflammatory cytokines interfere with this balance, not only by promoting increased lipoprotein uptake by LDL and scavenger receptors (6,7), but also by inhibiting ABCA1-mediated cholesterol efflux to HDL. Both PPAR and PPAR activation can reset the level of intracellular cholesterol by increasing ABCA1 gene expression, even in the presence of inflammatory cytokines, thereby potentially inhibiting foam cell formation. Such anti-atherogenic actions of PPAR activation are in keeping with studies of cholesterol accumulation in macrophages (14,31) and in LDL receptor knockout mice (32). These data would imply that pharmacologic agents such as fibrates and thiazolidinediones, which function as PPAR agonists, may protect against intracellular lipid accumulation. This may help to explain the protective role of such agents in animal models of lipid-induced renal injury (33,34). Such findings may also be relevant to other disease processes characterized by intracellular lipid deposition such as atherosclerosis.

	Acknowledgments

 
We would like to thank Roche Pharmaceuticals for providing Bezafibrate, acknowledge the support from the Royal Free Hospital Special Trustees through Grant-115.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260–269, 2001[CrossRef][Medline]
2. Moorhead JF, Chan MK, El-Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2: 1309–1311, 1982[Medline]
3. Diamond JR: Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 31: S29–34, 1991[Medline]
4. Brown MS Goldstein JL: A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA 96: 11041–11048, 1999[Abstract/Free Full Text]
5. Steinbrecher UP: Receptors for oxidized low density lipoprotein. Biochim Biophys Acta 1436: 279–298, 1999[Medline]
6. Ruan XZ, Varghese Z, Powis SH, Moorhead JF: Human mesangial cells express inducible macrophage scavenger receptor. Kidney Int 56: 440–451, 1999[CrossRef][Medline]
7. Ruan XZ, Varghese Z, Powis SH, Moorhead JF: Dysregulation of LDL receptor under the influence of inflammatory cytokines: A new pathway for foam cell formation. Kidney Int 60: 1716–1725, 2001[CrossRef][Medline]
8. Higgins CF: ABC transporters: Physiology, structure and mechanism — An overview. Res Microbiol 152: 205–210, 2001[Medline]
9. Higgins CF: Membrane permeability transporters and channels: From disease to structure and back. Curr Opin Cell Biol 11: 495, 1999[CrossRef][Medline]
10. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G: The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22: 347–351, 1999[CrossRef][Medline]
11. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G: Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 22: 352–355, 1999[CrossRef][Medline]
12. Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R, Schmitz G: ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport: Proc Natl Acad Sci USA 97: 817–822, 2000[Abstract/Free Full Text]
13. McNeish J, Aiello RJ, Guyot D, Turi T, Gabel C, Aldinger C, Hoppe KL, Roach ML, Royer LJ, de Wet J, Broccardo C, Chimini G, Francone OL: High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc Natl Acad Sci USA 97: 4245–4250, 2000[Abstract/Free Full Text]
14. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7: 53–58, 2001[CrossRef][Medline]
15. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P: Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 97: 12097–12102, 2000[Abstract/Free Full Text]
16. Costet P, Luo Y, Wang N, Tall AR: Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275: 28240–28245, 2000[Abstract/Free Full Text]
17. Pineda Torra I, Gervois P, Staels B: Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 10: 151–159, 1999[CrossRef][Medline]
18. Schoonjans K, Staels B, Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 907–925, 1996[Abstract]
19. Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82–86, 1998[CrossRef][Medline]
20. Sraer JD, Delarue F, Hagege J, Feunteun J, Pinet F, Nguyen G, Rondeau E: Stable cell lines of T-SV40 immortalized human glomerular mesangial cells. Kidney Int 49: 267–270, 1996[Medline]
21. Ruan XZ, Varghese Z, Fernando R, Moorhead JF: Cytokine regulation of low-density lipoprotein receptor gene transcription in human mesangial cells. Nephrol Dial Transplant 13: 1391–1397, 1998[Abstract/Free Full Text]
22. Ando M, Lundkvist I, Bergstrom J, Lindholm B: Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients. Kidney Int 49: 773–780, 1996[Medline]
23. Fernando RL, Varghese Z, Moorhead JF: Oxidation of low-density lipoproteins by rat mesangial cells and the interaction of oxidized low-density lipoproteins with rat mesangial cells in vitro. Nephrol Dial Transplant 8: 512–518, 1993[Abstract/Free Full Text]
24. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF: The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 104: R25–31, 1999
25. Orso E, Broccardo C, Kaminski WE, Bottcher A, Liebisch G, Drobnik W, Gotz A, Chambenoit O, Diederich W, Langmann T, Spruss T, Luciani MF, Rothe G, Lackner KJ, Chimini G, Schmitz G: Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat Genet 24: 192–196, 2000[CrossRef][Medline]
26. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648–658, 1999[CrossRef][Medline]
27. Issemann I Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347: 645–650, 1990[CrossRef][Medline]
28. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137: 354–366, 1996[Abstract]
29. Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, Gustafsson JA, Nebb HI: Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha. Mol Endocrinol 14: 741–752, 2000[Abstract/Free Full Text]
30. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P: A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis: Mol Cell 7: 161–171, 2001[CrossRef][Medline]
31. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW: The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7: 41–47, 2001[CrossRef][Medline]
32. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK: Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523–31, 2000[Medline]
33. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB: Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59: 1899–1910, 2001[CrossRef][Medline]
34. Kasiske BL, O’Donnell MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62: 367–374, 1988[Abstract/Free Full Text]

This article has been cited by other articles:

				X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF]

				Y. Chen, X. Z. Ruan, Q. Li, A. Huang, J. F. Moorhead, S. H. Powis, and Z. Varghese Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells Am J Physiol Renal Physiol, September 1, 2007; 293(3): F680 - F687. [Abstract] [Full Text] [PDF]

				K. L. Ma, X. Z. Ruan, S. H. Powis, J. F. Moorhead, and Z. Varghese Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2721 - H2728. [Abstract] [Full Text] [PDF]

				C. Berruyer, L. Pouyet, V. Millet, F. M. Martin, A. LeGoffic, A. Canonici, S. Garcia, C. Bagnis, P. Naquet, and F. Galland Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor {gamma} activity J. Exp. Med., December 25, 2006; 203(13): 2817 - 2827. [Abstract] [Full Text] [PDF]

				Y. Zhang, X. Zhang, L. Chen, J. Wu, D. Su, W. J. Lu, M.-T. Hwang, G. Yang, S. Li, M. Wei, et al. Liver X receptor agonist TO-901317 upregulates SCD1 expression in renal proximal straight tubule Am J Physiol Renal Physiol, May 1, 2006; 290(5): F1065 - F1073. [Abstract] [Full Text] [PDF]

				P. M. Hall Prevention of Progression in Diabetic Nephropathy Diabetes Spectr, January 1, 2006; 19(1): 18 - 24. [Abstract] [Full Text] [PDF]

				A. K. Berfield, A. Chait, J. F. Oram, R. A. Zager, A. C. Johnson, and C. K. Abrass IGF-1 induces rat glomerular mesangial cells to accumulate triglyceride Am J Physiol Renal Physiol, January 1, 2006; 290(1): F138 - F147. [Abstract] [Full Text] [PDF]

				S Soumian, R Gibbs, A Davies, and C Albrecht mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease J. Clin. Pathol., December 1, 2005; 58(12): 1255 - 1260. [Abstract] [Full Text] [PDF]

				M. Xia, M. Hou, H. Zhu, J. Ma, Z. Tang, Q. Wang, Y. Li, D. Chi, X. Yu, T. Zhao, et al. Anthocyanins Induce Cholesterol Efflux from Mouse Peritoneal Macrophages: THE ROLE OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR {gamma}-LIVER X RECEPTOR {alpha}-ABCA1 PATHWAY J. Biol. Chem., November 4, 2005; 280(44): 36792 - 36801. [Abstract] [Full Text] [PDF]

				Z. Varghese, R. Fernando, J. F. Moorhead, S. H. Powis, and X. Z. Ruan Effects of sirolimus on mesangial cell cholesterol homeostasis: a novel mechanism for its action against lipid-mediated injury in renal allografts Am J Physiol Renal Physiol, July 1, 2005; 289(1): F43 - F48. [Abstract] [Full Text] [PDF]

				S Soumian, C Albrecht, A. Davies, and R. Gibbs ABCA1 and atherosclerosis Vascular Medicine, May 1, 2005; 10(2): 109 - 119. [Abstract] [PDF]

				Y. Guan Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815. [Abstract] [Full Text] [PDF]

				J. Wu, Y. Zhang, N. Wang, L. Davis, G. Yang, X. Wang, Y. Zhu, M. D. Breyer, and Y. Guan Liver X receptor-{alpha} mediates cholesterol efflux in glomerular mesangial cells Am J Physiol Renal Physiol, November 1, 2004; 287(5): F886 - F895. [Abstract] [Full Text] [PDF]

				P. K. Chatterjee, N. S.A Patel, S. Cuzzocrea, P. A.J Brown, K. N Stewart, H. Mota-Filipe, D. Britti, W. Eberhardt, J. Pfeilschifter, and C. Thiemermann The cyclopentenone prostaglandin 15-deoxy-{Delta}12,14-prostaglandin J2 ameliorates ischemic acute renal failure Cardiovasc Res, February 15, 2004; 61(3): 630 - 643. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruan, X. Z. Articles by Varghese, Z. Search for Related Content PubMed PubMed Citation Articles by Ruan, X. Z. Articles by Varghese, Z.